+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Phenylketonuria (PKU): Market View - Product Thumbnail Image

Phenylketonuria (PKU): Market View

  • Report
  • March 2025
  • 72 Pages
  • Global
From
Type 1 Diabetes (Juvenile Diabetes) - Global Clinical Trials Review, 2025 - Product Thumbnail Image

Type 1 Diabetes (Juvenile Diabetes) - Global Clinical Trials Review, 2025

  • Clinical Trials
  • March 2025
  • 1657 Pages
  • Global
From
Diabetic Foot Ulcers - Global Clinical Trials Review, 2025 - Product Thumbnail Image

Diabetic Foot Ulcers - Global Clinical Trials Review, 2025

  • Clinical Trials
  • February 2025
  • 390 Pages
  • Global
From
Diabetic Nephropathy - Global Clinical Trials Review, 2025 - Product Thumbnail Image

Diabetic Nephropathy - Global Clinical Trials Review, 2025

  • Clinical Trials
  • January 2025
  • 615 Pages
  • Global
From
Hyperthyroidism - Global Clinical Trials Review, 2024 - Product Thumbnail Image

Hyperthyroidism - Global Clinical Trials Review, 2024

  • Clinical Trials
  • December 2024
  • 117 Pages
  • Global
From
Type 1 Diabetes: Seven-Market Drug Forecast and Market Analysis - Product Thumbnail Image

Type 1 Diabetes: Seven-Market Drug Forecast and Market Analysis

  • Report
  • December 2024
  • 144 Pages
  • Global
From
Type 1 Diabetes: Epidemiology Forecast to 2033 - Product Thumbnail Image

Type 1 Diabetes: Epidemiology Forecast to 2033

  • Report
  • November 2024
  • 69 Pages
  • Global
From
Glycogen Storage Disorders (GSD): Competitive Landscape - Product Thumbnail Image

Glycogen Storage Disorders (GSD): Competitive Landscape

  • Report
  • September 2024
  • 77 Pages
  • Global
From
Turner Syndrome Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Turner Syndrome Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Somatotropin Deficiency Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Somatotropin Deficiency Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
GLP-1 Agonists Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

GLP-1 Agonists Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Type 2 Diabetes Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Type 2 Diabetes Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Phenylketonuria (PKU) Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Phenylketonuria (PKU) Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Osteoporosis Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Osteoporosis Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Hypoparathyroidism Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Hypoparathyroidism Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Hypoglycemia Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Hypoglycemia Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Hypertriglyceridemia Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Hypertriglyceridemia Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Fabry Disease Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Fabry Disease Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Diabetic Neuropathic Pain Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Diabetic Neuropathic Pain Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Diabetic Gastroparesis Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Diabetic Gastroparesis Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more